Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Brain Research Bulletin

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0361-9230(94)90285-2PMID 8124580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Catecholamine stimulation of copper dependent haemolysis: protective action of superoxide dismutase, catalase, hydroxyl radical scavengers and serum proteins (ceruloplasmin, albumin and apotransferrin).

  2009cited by this paper
• Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers

  1993cited by this paper
• Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.

  1993cited by this paper
• Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.

  1993cited by this paper
• Are dopaminergic neurons selectively vulnerable to Parkinson's disease?

  1993cited by this paper
• The pharmacology of Parkinson's disease therapy: an update.

  1993cited by this paper
• Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.

  1993cited by this paper
• Biochemical aspects of Parkinson's disease.

  1993cited by this paper
• Inhibition of nigral dopamine neurons by systemic and local apomorphine: possible contribution of dendritic autoreceptors.

  1992cited by this paper
• Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.

  1992cited by this paper
• Determination of release of endogenous dopamine from superfused substantia nigra slices.

  1992cited by this paper
• Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis

  1992cited by this paper
• Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.

  1992cited by this paper
• Iron induces degeneration of nigrostriatal neurons.

  1992cited by this paper
• Dopa and dopamine cause cultured neuronal death in the presence of iron.

  1991cited by this paper
• The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons

  1991cited by this paper
• Role of Dendritic Dopamine of the Substantia Nigra in the Modulation of Nigrocollicular γ‐Aminobutyric Acid Release: In Vivo Studies in the Rat

  1991cited by this paper
• Iron in brain function and dysfunction with emphasis on Parkinson's disease.

  1991cited by this paper
• Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease

  1991cited by this paper
• Oxidative stress as a cause of Parkinson's disease

  1991cited by this paper
• Hydrogen peroxide dependent oxidative degradation of DNA by copper epinephrine.

  1991cited by this paper
• Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats

  1991cited by this paper
• Inhibition of lipid peroxidation by methylated analogues of uric acid

  1991cited by this paper
• Transition metals as catalysts of "autoxidation" reactions.

  1990cited by this paper
• The effects of haloperidol and amphetamine on ascorbic acid and uric acid in caudate and nucleus accumbens of rats as measured by voltammetry in vivo.

  1990cited by this paper
• Uric acid levels and dopamine transmission in rat striatum: diurnal changes and effects of drugs.

  1990cited by this paper
• Lever pressing for food reward and changes in dopamine turnover and uric acid in rat caudate and nucleus accumbens studied chronically by in vivo voltammetry.

  1990cited by this paper
• Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

  1989cited by this paper
• Manganese catalysis of dopamine oxidation.

  1989cited by this paper
• The Endogenous Toxin Hypothesis of the Etiology of Parkinson's Disease and a Pilot Trial of High‐Dosage Antioxidants in an Attempt to Slow the Progression of the Illness

  1989cited by this paper
• Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?

  1989cited by this paper
• Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

  1989cited by this paper
• Enhancement by catechols of hydroxyl-radical formation in the presence of ferric ions and hydrogen peroxide.

  1989cited by this paper
• Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?

  1989cited by this paper
• Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

  1989cited by this paper
• A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra

  1989cited by this paper
• Iron and Oxygen: A Biologically Damaging Mixture

  1989cited by this paper
• Formation of hydroxyl radicals from hydrogen peroxide in the presence of iron. Is haemoglobin a biological Fenton reagent?

  1988cited by this paper
• Studies on the autoxidation of dopamine: interaction with ascorbate.

  1988cited by this paper
• Intracranial dialysis measurement of oxytocin, monoamine and uric acid release from the olfactory bulb and substantia nigra of sheep during parturition, suckling, separation from lambs and eating.

  1988cited by this paper
• The effect of melanin on iron associated decomposition of hydrogen peroxide.

  1988cited by this paper
• Copper catalyzed oxidation of ascorbate (vitamin C). Inhibitory effect of catalase, superoxide dismutase, serum proteins (ceruloplasmin, albumin, apotransferrin) and amino acids.

  1987cited by this paper
• Voltammetric evidence in vivo of cholinergic modulation of extracellular ascorbic acid and uric acid in rat striatum.

  1987cited by this paper
• Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.

  1987cited by this paper
• Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid.

  1986cited by this paper
• Iron and free radical reactions: two aspects of antioxidant protection

  1986cited by this paper
• Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts.

  1986cited by this paper
• Uric acid is released in the zona incerta of the subthalamic region of the sheep during rumination and in response to feeding and drinking stimuli.

  1986cited by this paper
• In vivo voltammetric evidence of production of uric acid by rat caudate.

  1985cited by this paper
• Glutathione peroxidase activity in Parkinson's disease brain.

  1985cited by this paper
• Conservation of vitamin C by uric acid in blood.

  1985cited by this paper
• The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.

  1985cited by this paper
• Peroxidatic oxidation of catecholamines. A kinetic electron spin resonance investigation using the spin stabilization approach.

  1984cited by this paper
• Urate and ascorbate: their possible roles as antioxidants in determining longevity of mammalian species.

  1984cited by this paper
• Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates.

  1984cited by this paper
• Uric acid: functions and determination.

  1984cited by this paper
• Measurement of uric acid, ascorbic acid, and related metabolites in biological fluids.

  1984cited by this paper
• Inhibition of free radical‐induced DNA damage by uric acid

  1984cited by this paper
• Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease.

  1984cited by this paper
• Catecholamine toxicity : a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease

  1984cited by this paper
• [19] Uric acid: Functions and determination

  1984cited by this paper
• On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.

  1983cited by this paper
• Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

  1981cited by this paper
• Stimulatory and inhibitory effects of manganous and ferrous ions on epinephrine oxidation.

  1979cited by this paper
• Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

  1978cited by this paper
• Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro.

  1978cited by this paper
• Brain peroxidase and catalase in Parkinson disease.

  1975cited by this paper
• Similar Functions of Uric Acid and Ascorbate in Man ?

  1970cited by this paper

• Association between higher serum uric acid levels and cognitive function: a systematic review and meta-analysis

  2025cites this paper
• Progress in Surface Plasmon and Other Resonance Biosensors for Biomedical Applications

  2025cites this paper
• A review of the evidence for a protective role of uric acid in Parkinson’s disease

  2025cites this paper
• Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases

  2025cites this paper
• Impact of Nutrition on the Gut Microbiota: Implications for Parkinson's Disease.

  2025cites this paper
• Association Between Serum Uric Acid Level and the Severity of Parkinsons Disease: A cross sectional study

  2024cites this paper
• Relationships between Serum Lipid, Uric Acid Levels and Mild Cognitive Impairment in Parkinson's Disease and Multiple System Atrophy.

  2024cites this paper
• Clinical findings of hyperechoic substantia nigra in patients with Parkinson's disease

  2024cites this paper
• Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson ’ s disease Níveis séricos baixos de ácido úrico e discinesia induzida por levodopa na doença de Parkinson

  2023cites this paper
• Silkworm Bombyx mori as a model organism: A review

  2023cites this paper
• Disorders of Endogenous and Exogenous Antioxidants in Neurological Diseases

  2023cites this paper
• Serum uric acid and Parkinson's disease: A systematic review and meta‐analysis

  2023cites this paper
• Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson ’ s disease Níveis séricos baixos de ácido úrico e discinesia induzida por levodopa na doença de Parkinson

  2023cites this paper
• Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study

  2022cites this paper
• Serum Uric Acid Levels in Parkinson’s Disease: A Cross-Sectional Electronic Medical Record Database Study from a Tertiary Referral Centre in Romania

  2022cites this paper
• Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

  2022cites this paper
• Association of Serum Uric Acid Levels in Meige’s Syndrome

  2021cites this paper
• Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson’s disease

  2021cites this paper
• Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis

  2021cites this paper
• A comparative study for evaluation of uric acid among age-wise and gender-wise in district Toba Tek Singh

  2021cites this paper
• Available treatment options for hyperuricemic patients

  2021cites this paper
• Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?

  2021cites this paper
• Risk of Parkinson’s disease following gout: a population-based retrospective cohort study in Taiwan

  2020cites this paper
• A Study of the Relationship Between Uric Acid and Substantia Nigra Brain Connectivity in Patients With REM Sleep Behavior Disorder and Parkinson's Disease

  2020cites this paper
• Gender-specific effect of urate on white matter integrity in Parkinson's disease.

  2020cites this paper
• Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington’s Patients

  2020cites this paper
• Serum Uric Acid, Serum Uric Acid to Serum Creatinine Ratio and Serum Bilirubin in Patients With Parkinson’s Disease: A Case-Control Study

  2020cites this paper
• Risk of Parkinson disease Following Gout: A Population-Based Retrospective Cohort Study in Taiwan

  2020cites this paper
• Research Progress of the Relationship between Uric Acid and Disease

  2020influential citation
• Biochemical Markers in Parkinson's Disease

  2020cites this paper
• Biomarkers of Parkinson's Disease

  2019cites this paper
• Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data

  2019cites this paper
• Serum Uric Acid Level as a Prognostic Marker in Patients With Acute Respiratory Distress Syndrome

  2019cites this paper
• Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort

  2019influential citation
• Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?

  2019cites this paper
• Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease.

  2019cites this paper
• ZIP-5/bZIP transcription factor regulation of folate metabolism is critical for aging axon regeneration

  2019cites this paper
• Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?

  2019cites this paper
• Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.

  2019cites this paper
• Association between carotid plaque and Parkinson's disease.

  2019cites this paper
• Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson’s disease

  2018cites this paper
• Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model

  2018cites this paper
• Peripheral Biomarkers for Early Detection of Alzheimer’s and Parkinson’s Diseases

  2018cites this paper
• Plasma urate and risk of Parkinson's disease: A mendelian randomization study

  2018cites this paper
• Porous tal palm carbon nanosheets: preparation, characterization and application for the simultaneous determination of dopamine and uric acid

  2018cites this paper
• Vésicules extracellulaires : biomarqueurs et véhicules de propagation de protéinopathies

  2018cites this paper
• Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson’s Disease Models

  2018cites this paper
• Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?

  2017cites this paper
• Serum uric acid levels and freezing of gait in Parkinson’s disease

  2017cites this paper
• MANAGEMENT OF HYPERURICEMIA AND GOUT BY PREBIOTICS AND PROBIOTICS: POTENTIALS AND LIMITATIONS

  2017cites this paper
• Sex-Dependent Associations of Serum Uric Acid with Brain Function During Aging

  2017cites this paper
• Urate promotes SNCA/α-synuclein clearance via regulating mTOR-dependent macroautophagy.

  2017cites this paper
• Targeting urate to reduce oxidative stress in Parkinson disease.

  2017cites this paper
• The Single Nucleotide Polymorphism rs1014290 of the SLC2A9 Gene Is Associated with Uric Acid Metabolism in Parkinson's Disease

  2017cites this paper
• Uric acid demonstrates neuroprotective effect on Parkinson's disease mice through Nrf2-ARE signaling pathway.

  2017cites this paper
• Potential mechanisms for low uric acid in Parkinson disease

  2016cites this paper
• Serum Uric Acid and Its Association with Longitudinal Cognitive Change Among Urban Adults

  2016cites this paper
• Urate as a Marker of Risk and Progression of Neurodegenerative Disease

  2016cites this paper
• Can the silkworm (Bombyx mori) be used as a human disease model?

  2016cites this paper
• An Initial Analysis of a Long-Term Ketogenic Diet’s Impact on Motor Behavior, Brain Purine Systems, and Nigral Dopamine Neurons in a New Genetic Rodent Model of Parkinson’s Disease

  2016cites this paper
• The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease

  2016cites this paper
• Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies

  2015cites this paper
• Association of Serum Uric Acid and Parkinson’s Disease: A Case Control Study

  2015cites this paper
• Uric Acid: A Biomarker to Predict Clinical Progression of Parkinson Disease

  2015cites this paper
• The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.

  2015cites this paper
• Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis.

  2015cites this paper
• Complex liaisons moving forward the Parkinson’s disease? An appraisal

  2015cites this paper
• Serum uric acid level as a prognostic factor in benign essential tremor.

  2015cites this paper
• Purines in Parkinson’s: Adenosine A2A Receptors and Urate as Targets for Neuroprotection

  2015cites this paper
• Abnormal Serum Uric Acid Levels in Health and Disease: A Double-Edged Sword

  2014cites this paper
• Uric acid and central nervous system functioning (a literature review)

  2014cites this paper
• Identificação de biomarcadores em fluidos biológicos para o diagnóstico precoce da Doença de Parkinson: Realidade ou Utopia?

  2014cites this paper
• Serum Uric Acid and Nigral Iron Deposition in Parkinson’s Disease: A Pilot Study

  2014cites this paper
• Emerging candidate biomarkers for Parkinson's disease: a review.

  2014cites this paper
• Comorbidities in patients with crystal diseases and hyperuricemia.

  2014cites this paper
• Nrf2 Signaling Contributes to the Neuroprotective Effects of Urate against 6-OHDA Toxicity

  2014cites this paper
• Association of Serum Uric Acid with Parkinson Disease

  2013cites this paper
• Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis

  2013cites this paper
• Serum Urate and the Risk of Parkinson's Disease: Results From a Meta-Analysis

  2013cites this paper
• Associations of Serum Uric Acid and SLC2A9 Variant with Depressive and Anxiety Disorders: A Population-Based Study

  2013cites this paper
• Identification of Key Uric Acid Synthesis Pathway in a Unique Mutant Silkworm Bombyx mori Model of Parkinson’s Disease

  2013cites this paper
• Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis

  2013cites this paper
• Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders

  2013cites this paper
• Low serum uric acid concentration in Parkinson's disease in southern Spain

  2013cites this paper
• Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression.

  2013cites this paper
• Gout and the risk of Parkinson’s disease in Denmark

  2013cites this paper
• For peer review only Low uric acid levels in patients with Parkinson's disease

  2013cites this paper
• Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease

  2013cites this paper
• Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.

  2012cites this paper
• Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO

  2012cites this paper
• Serum Uric Acid in Patients with Parkinson’s Disease and Vascular Parkinsonism: A Cross-Sectional Study

  2012cites this paper
• Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action.

  2012cites this paper
• Neuroprotection by urate on 6‐OHDA‐lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway

  2012cites this paper
• Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro.

  2012cites this paper
• Award Number: W81XWH-11-1-0150 TITLE: Protection by Purines in Toxin Models of Parkinson's Disease PRINCIPAL INVESTIGATOR:

  2012cites this paper
• Urate in Parkinson’s Disease: More Than a Biomarker?

  2012cites this paper
• Urate and Its Transgenic Depletion Modulate Neuronal Vulnerability in a Cellular Model of Parkinson's Disease

  2012cites this paper
• Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration

  2012cites this paper
• Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View

  2011cites this paper
• Urate as a marker of development and progression in Parkinson's disease.

  2011cites this paper